Form D · Biotechnology
Rejuvitas, Inc.
New York, NY · CIK 0001905945
Offering snapshot reported Sep 7, 2022 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 31, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 7, 2022 | Initial | $4,999,996 | No comparison | 3 | SEC filing |
| Jan 25, 2022 | Initial | $3,300,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-458186
Source: Form D, filed Sep 7, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Heil | Director |
| Joni Mancini | Executive |
| John Prufeta | Director |
| Andrea Spezzi | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
The Lasker Biomedical Research Building 3960 Broadway, 6th Floor
New York, NY, 10032
New York, NY, 10032